Virax Biolabs Group (NASDAQ:VRAX) Upgraded by Wall Street Zen to Hold Rating

Virax Biolabs Group (NASDAQ:VRAX) was upgraded by stock analysts at Wall Street Zen to a “hold” rating in a report released on Saturday.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Virax Biolabs Group in a report on Wednesday, April 8th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $1.00.

Virax Biolabs Group Price Performance

Virax Biolabs Group stock opened at $3.11 on Friday. The company’s 50 day simple moving average is $0.24 and its 200 day simple moving average is $0.26. Virax Biolabs Group has a fifty-two week low of $2.50 and a fifty-two week high of $28.50.

Virax Biolabs Group Company Profile

Virax Biolabs Group (NASDAQ: VRAX) is a clinical-stage biotechnology company focused on the research, development and manufacturing of next-generation vaccines targeting respiratory and other infectious diseases. Headquartered in Australia, the company leverages advanced viral vector platforms to create novel immunization solutions designed to induce both systemic and mucosal immunity. Virax Biolabs is publicly traded on the NASDAQ exchange under the symbol VRAX.

At the core of Virax Biolabs’ pipeline is a proprietary adenoviral vector platform, licensed exclusively from a leading academic institution, which serves as the backbone for intranasal and injectable vaccine candidates.